<p>enGene Holdings Inc. (NASDAQ:ENGN - 獲取免費報告) 的股票在週二交易中上漲了 4.6%。該公司的股價最高達到 9.06 美元，最後交易價為 9.1760 美元。在交易中，共成交了 4,166 股，較平均交易量 403,350 股下降了 99%。該股票之前的收盤價為 8.77 美元。</p>
<h2>華爾街分析師預測增長</h2>
<p>幾位分析師最近對 ENGN 股票發表了看法。HC Wainwright 在 12 月 3 日的報告中重申了 “買入” 評級，並設定了 25.00 美元的目標價。瑞銀集團將 enGene 的目標價從 4.00 美元上調至 10.00 美元，並在 11 月 12 日的報告中給予該股票 “中性” 評級。Weiss Ratings 在 10 月 14 日的研究報告中重申了 enGene 的 “賣出（d-）” 評級。花旗集團在 11 月 12 日的研究報告中重申了 enGene 的 “市場表現優於大盤” 評級。最後，Raymond James Financial 將 enGene 的評級從 “表現優於大盤” 上調至 “強力買入”，並在 11 月 11 日的報告中設定了 27.00 美元的目標價。一位股票研究分析師給予該股票 “強力買入” 評級，七位給予 “買入” 評級，一位給予 “持有” 評級，一位給予 “賣出” 評級。根據 MarketBeat.com 的數據，enGene 目前的平均評級為 “適度買入”，共識目標價為 22.38 美元。</p>
<p><strong>查看我們關於 ENGN 的最新報告</strong></p>
<h2>enGene 股票表現</h2>
<p>該公司的市值為 5.922 億美元，市盈率為-4.83，貝塔值為-0.28。公司的債務與股本比率為 0.09，流動比率為 10.34，速動比率為 10.34。該股票的 50 日移動平均線為 7.89 美元，200 日移動平均線為 5.79 美元。</p>
<p>enGene (NASDAQ:ENGN - 獲取免費報告) 最近在 12 月 22 日發佈了季度財報。該公司報告每股收益（EPS）為-0.73 美元，低於共識預期的-0.55 美元，差額為-0.18 美元。整體來看，股票分析師預計 enGene Holdings Inc.在當前財年將發佈-1.56 美元的每股收益。</p>
<h2>enGene 的機構交易</h2>
<p>幾家對沖基金最近增加或減少了在 ENGN 的持股。Braidwell LP 在第三季度以約 15,479,000 美元的估值收購了 enGene 的新頭寸。Adage Capital Partners GP L.L.C.在第一季度將其在 enGene 的持股增加了 2.7%。Adage Capital Partners GP L.L.C.目前擁有 1,571,642 股該公司的股票，估值為 7,041,000 美元，此前在上個季度增持了 41,874 股。MAI Capital Management 在第一季度將其在 enGene 的持股增加了 11.0%。MAI Capital Management 目前擁有 78,067 股該公司的股票，價值 350,000 美元，此前在此期間增持了 7,756 股。Affinity Asset Advisors LLC 在第二季度以約 280,000 美元的估值購買了 enGene 的新頭寸。最後，Citadel Advisors LLC 在第三季度將其在 enGene 的持股增加了 153.3%。Citadel Advisors LLC 目前擁有 58,370 股該公司的股票，估值為 399,000 美元，此前在上個季度增持了 35,327 股。機構投資者和對沖基金持有該公司 64.16% 的股票。</p>
<h2>enGene 公司簡介</h2>
<p>(獲取免費報告)</p>
<p>enGene, Inc 是一家臨牀階段的生物製藥公司，專注於開發基於基因的腫瘤治療藥物。該公司的核心技術是 EnGene 遞送載體（EDV）平台，該平台利用非活性、細菌衍生的微小細胞直接將治療藥物輸送到腫瘤細胞。通過將靶向遞送與強效藥物結合，enGene 旨在提高癌症治療的精準性和有效性，同時減少非靶向毒性。</p>
<p>通過其 EDV 平台，enGene 已將多個治療候選藥物推進到臨牀前和臨牀階段。</p>
<h2>瞭解更多</h2>
<ul>
<li>五隻我們更看好的股票，勝過 enGene</li>
<li>請勿刪除，立即閲讀</li>
<li>投資者警報：微型 “$3 AI 奇蹟股票” 即將爆發</li>
<li>埃隆警告 “美國破產”。特朗普的計劃在此。</li>
<li>任何費用可以從資本利得税中扣除嗎？</li>
<li>巴菲特、蓋茨和貝索斯悄悄拋售股票——原因在這裏</li>
</ul>
<p><em>此即時新聞警報由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 enGene 嗎？</h2>
<p>在你考慮 enGene 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前立即購買……而 enGene 並不在名單上。</p>
<p>雖然 enGene 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

ENGN

<p>enGene（納斯達克代碼：ENGN）股價上漲 4.6%，至 9.1760 美元，交易量顯著低於平均水平。分析師的評級意見不一，普遍共識為 “適度買入”，目標價為 22.38 美元。該公司專注於基於基因的癌症治療。近期有機構投資的消息被提及。enGene 報告的季度每股虧損為 0.73 美元，未能達到預期。市值為 5.922 億美元</p>

<p>enGene Holdings Inc. (NASDAQ:ENGN - Get Free Report) shares shot up 4.6% during trading on Tuesday . The company traded as high as $9.06 and last traded at $9.1760. 4,166 shares traded hands during trading, a decline of 99% from the average session volume of 403,350 shares. The stock had previously closed at $8.77.</p>
<div class="lb-trans"><p>enGene Holdings Inc. (NASDAQ:ENGN - 獲取免費報告) 的股票在週二交易中上漲了 4.6%。該公司的股價最高達到 9.06 美元，最後交易價為 9.1760 美元。在交易中，共成交了 4,166 股，較平均交易量 403,350 股下降了 99%。該股票之前的收盤價為 8.77 美元。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>華爾街分析師預測增長</h2>
</div><p>Several analysts have recently weighed in on ENGN shares. HC Wainwright reissued a &#34;buy&#34; rating and set a $25.00 price objective on shares of enGene in a report on Wednesday, December 3rd. UBS Group raised their price objective on shares of enGene from $4.00 to $10.00 and gave the stock a &#34;neutral&#34; rating in a report on Wednesday, November 12th. Weiss Ratings reiterated a &#34;sell (d-)&#34; rating on shares of enGene in a research report on Tuesday, October 14th. Citigroup reissued a &#34;market outperform&#34; rating on shares of enGene in a research report on Wednesday, November 12th. Finally, Raymond James Financial raised enGene from an &#34;outperform&#34; rating to a &#34;strong-buy&#34; rating and set a $27.00 price objective on the stock in a report on Tuesday, November 11th. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, enGene presently has an average rating of &#34;Moderate Buy&#34; and a consensus price target of $22.38.</p>
<div class="lb-trans"><p>幾位分析師最近對 ENGN 股票發表了看法。HC Wainwright 在 12 月 3 日的報告中重申了 “買入” 評級，並設定了 25.00 美元的目標價。瑞銀集團將 enGene 的目標價從 4.00 美元上調至 10.00 美元，並在 11 月 12 日的報告中給予該股票 “中性” 評級。Weiss Ratings 在 10 月 14 日的研究報告中重申了 enGene 的 “賣出（d-）” 評級。花旗集團在 11 月 12 日的研究報告中重申了 enGene 的 “市場表現優於大盤” 評級。最後，Raymond James Financial 將 enGene 的評級從 “表現優於大盤” 上調至 “強力買入”，並在 11 月 11 日的報告中設定了 27.00 美元的目標價。一位股票研究分析師給予該股票 “強力買入” 評級，七位給予 “買入” 評級，一位給予 “持有” 評級，一位給予 “賣出” 評級。根據 MarketBeat.com 的數據，enGene 目前的平均評級為 “適度買入”，共識目標價為 22.38 美元。</p>
</div><p><strong>View Our Latest Report on ENGN</strong></p>
<div class="lb-trans"><p><strong>查看我們關於 ENGN 的最新報告</strong></p>
</div><h2>enGene Stock Performance</h2>
<div class="lb-trans"><h2>enGene 股票表現</h2>
</div><p>The firm has a market capitalization of $592.20 million, a P/E ratio of -4.83 and a beta of -0.28. The company has a debt-to-equity ratio of 0.09, a current ratio of 10.34 and a quick ratio of 10.34. The stock's 50 day moving average is $7.89 and its two-hundred day moving average is $5.79.</p>
<div class="lb-trans"><p>該公司的市值為 5.922 億美元，市盈率為-4.83，貝塔值為-0.28。公司的債務與股本比率為 0.09，流動比率為 10.34，速動比率為 10.34。該股票的 50 日移動平均線為 7.89 美元，200 日移動平均線為 5.79 美元。</p>
</div><p>enGene (NASDAQ:ENGN - Get Free Report) last posted its quarterly earnings results on Monday, December 22nd. The company reported ($0.73) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.55) by ($0.18). As a group, equities analysts anticipate that enGene Holdings Inc. will post -1.56 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>enGene (NASDAQ:ENGN - 獲取免費報告) 最近在 12 月 22 日發佈了季度財報。該公司報告每股收益（EPS）為-0.73 美元，低於共識預期的-0.55 美元，差額為-0.18 美元。整體來看，股票分析師預計 enGene Holdings Inc.在當前財年將發佈-1.56 美元的每股收益。</p>
</div><h2>Institutional Trading of enGene</h2>
<div class="lb-trans"><h2>enGene 的機構交易</h2>
</div><p>Several hedge funds have recently added to or reduced their stakes in ENGN. Braidwell LP acquired a new position in shares of enGene in the 3rd quarter valued at approximately $15,479,000. Adage Capital Partners GP L.L.C. lifted its position in enGene by 2.7% in the 1st quarter. Adage Capital Partners GP L.L.C. now owns 1,571,642 shares of the company's stock valued at $7,041,000 after acquiring an additional 41,874 shares in the last quarter. MAI Capital Management boosted its stake in enGene by 11.0% in the 1st quarter. MAI Capital Management now owns 78,067 shares of the company's stock worth $350,000 after purchasing an additional 7,756 shares during the period. Affinity Asset Advisors LLC bought a new position in enGene during the 2nd quarter worth about $280,000. Finally, Citadel Advisors LLC lifted its holdings in shares of enGene by 153.3% in the third quarter. Citadel Advisors LLC now owns 58,370 shares of the company's stock valued at $399,000 after purchasing an additional 35,327 shares in the last quarter. Institutional investors and hedge funds own 64.16% of the company's stock.</p>
<div class="lb-trans"><p>幾家對沖基金最近增加或減少了在 ENGN 的持股。Braidwell LP 在第三季度以約 15,479,000 美元的估值收購了 enGene 的新頭寸。Adage Capital Partners GP L.L.C.在第一季度將其在 enGene 的持股增加了 2.7%。Adage Capital Partners GP L.L.C.目前擁有 1,571,642 股該公司的股票，估值為 7,041,000 美元，此前在上個季度增持了 41,874 股。MAI Capital Management 在第一季度將其在 enGene 的持股增加了 11.0%。MAI Capital Management 目前擁有 78,067 股該公司的股票，價值 350,000 美元，此前在此期間增持了 7,756 股。Affinity Asset Advisors LLC 在第二季度以約 280,000 美元的估值購買了 enGene 的新頭寸。最後，Citadel Advisors LLC 在第三季度將其在 enGene 的持股增加了 153.3%。Citadel Advisors LLC 目前擁有 58,370 股該公司的股票，估值為 399,000 美元，此前在上個季度增持了 35,327 股。機構投資者和對沖基金持有該公司 64.16% 的股票。</p>
</div><h2>enGene Company Profile</h2>
<div class="lb-trans"><h2>enGene 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(獲取免費報告)</p>
</div><p>enGene, Inc is a clinical‐stage biopharmaceutical company focused on the development of gene‐based therapeutics for oncology. The company’s core technology is the EnGene Delivery Vehicle (EDV) platform, which employs nonliving, bacterially derived minicells to transport therapeutic payloads directly to tumor cells. By combining targeted delivery with potent payloads, enGene aims to improve the precision and efficacy of cancer treatments while reducing off‐target toxicity.</p>
<div class="lb-trans"><p>enGene, Inc 是一家臨牀階段的生物製藥公司，專注於開發基於基因的腫瘤治療藥物。該公司的核心技術是 EnGene 遞送載體（EDV）平台，該平台利用非活性、細菌衍生的微小細胞直接將治療藥物輸送到腫瘤細胞。通過將靶向遞送與強效藥物結合，enGene 旨在提高癌症治療的精準性和有效性，同時減少非靶向毒性。</p>
</div><p>Through its EDV platform, enGene has advanced multiple therapeutic candidates into preclinical and clinical stages.</p>
<div class="lb-trans"><p>通過其 EDV 平台，enGene 已將多個治療候選藥物推進到臨牀前和臨牀階段。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>瞭解更多</h2>
</div><ul>
<li>Five stocks we like better than enGene</li>
<li>Do not delete, read immediately</li>
<li>INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off</li>
<li>Elon Warns “America Is Broke”. Trump’s Plan Inside.</li>
<li>Can Any Expenses Be Deducted From Capital Gains Tax?</li>
<li>Buffett, Gates and Bezos Quietly Dumping Stocks—Here's Why</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，勝過 enGene</li>
<li>請勿刪除，立即閲讀</li>
<li>投資者警報：微型 “$3 AI 奇蹟股票” 即將爆發</li>
<li>埃隆警告 “美國破產”。特朗普的計劃在此。</li>
<li>任何費用可以從資本利得税中扣除嗎？</li>
<li>巴菲特、蓋茨和貝索斯悄悄拋售股票——原因在這裏</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞警報由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in enGene Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 enGene 嗎？</h2>
</div><p>Before you consider enGene, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 enGene 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and enGene wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前立即購買……而 enGene 並不在名單上。</p>
</div><p>While enGene currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 enGene 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

enGene（NASDAQ:ENGN）股價上漲 4.6% - 接下來會發生什麼？